Want to see RGEN full AI Analyst Report?
RGEN Stock Chart & Stats
$131.21
$0.11(0.07%)
At close: 4:00 PM EST
$131.21
$0.11(0.07%)
Day’s Range― - ―
52-Week Range$100.99 - $175.77
Previous CloseN/A
Volume111.19K
Average Volume (3M)975.93K
Market Cap
$7.73B
Enterprise Value$6.58K
Total Cash (Recent Filing)$784.53M
Total Debt (Recent Filing)$687.62M
Price to Earnings (P/E)154.3
Beta0.98
Next Earnings
Jul 28, 2026EPS Estimate
0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.91
Shares Outstanding56,407,740
10 Day Avg. Volume724,201
30 Day Avg. Volume975,933
Financial Highlights & Ratios
PEG Ratio-0.65
Price to Book (P/B)4.38
Price to Sales (P/S)12.48
P/FCF Ratio98.13
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$165.36Price Target Upside26.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)2
Revenue Forecast (FY)$822.37M
Bulls Say, Bears Say
Bulls Say
Strong Cash Balance And Balance-sheet FlexibilityA large cash stockpile and manageable leverage provide durable strategic optionality. With $785M on hand and pro forma cash expected above $300M after the BioLife acquisition, Repligen can fund M&A, absorb cyclical downtimes, invest in R&D and capex, and pursue synergies without immediate financing strain.
Return To Profitability And Expanding MarginsRepligen has moved back to sustained profitability with meaningful margin expansion driven by product mix and cost discipline. Recent gross- and operating-margin gains, plus guidance for continued margin improvement and a transformation office, suggest more durable earnings quality and operating leverage over the medium term.
Acquisition Expands Cell Therapy And Synergy PotentialBuying BioLife meaningfully broadens exposure to the high-growth cell therapy addressable market and adds a proven biopreservation platform used by commercial therapies. The deal is structured to be EPS- and margin-accretive with quantified near-term synergies, offering lasting revenue diversification and cross-sell potential.
Bears Say
Uneven Multi-year Revenue And Margin ConsistencyRepligen's revenue and margin trajectory has been volatile across recent years, with a notable decline then a bumpy recovery. This uneven multi-year pattern and below-peak profitability increase forecasting risk, make long-term margin normalization uncertain, and require consistent execution to sustain improvements.
Capital-equipment And Customer Timing LumpinessA material portion of revenue is tied to larger capital orders whose timing depends on customer facility readiness and budget cycles. That structural lumpy cadence can lead to volatile quarter-to-quarter results and delayed margin benefits, complicating planning and smoothing of long-term earnings.
Competitive Pressure And China Localization RiskFaster growth in APAC is offset by rising local competition requiring onshore manufacturing and partnerships. The multi-year OEM ramp and localization effort introduces execution risk, potential margin pressure while building local capabilities, and uncertain timing to reclaim share in a competitive Chinese market.
Repligen News
RGEN FAQ
What was Repligen’s price range in the past 12 months?
Repligen lowest stock price was $100.99 and its highest was $175.77 in the past 12 months.
What is Repligen’s market cap?
Repligen’s market cap is $7.73B.
When is Repligen’s upcoming earnings report date?
Repligen’s upcoming earnings report date is Jul 28, 2026 which is in 5 days.
How were Repligen’s earnings last quarter?
Repligen released its earnings results on May 05, 2026. The company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.384 by $0.096.
Is Repligen overvalued?
According to Wall Street analysts Repligen’s price is currently Undervalued.
Does Repligen pay dividends?
Repligen does not currently pay dividends.
What is Repligen’s EPS estimate?
Repligen’s EPS estimate is 0.45.
How many shares outstanding does Repligen have?
Repligen has 56,407,740 shares outstanding.
What happened to Repligen’s price movement after its last earnings report?
Repligen reported an EPS of $0.48 in its last earnings report, beating expectations of $0.384. Following the earnings report the stock price went up 6.26%.
Which hedge fund is a major shareholder of Repligen?
Currently, no hedge funds are holding shares in RGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Repligen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$165.36 (26.03% Upside)
$165.36 (26.03% Upside)
Blogger Sentiment
Bearish
RGEN Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 6.6%
Last 30 Days ▲ 6.6%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.32%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.76%
Trailing 12-Months
Company Description
Repligen
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
RGEN Revenue Breakdown
44.00% North America
37.00% Europe
19.00% APAC/Other
RGEN Stock 12 Month Forecast
Average Price Target
$165.36
▲(26.03% Upside)
Technical Analysis
AptarGroup
―
Merit Medical Systems
―
Teleflex
―
Stevanato Group
―
Bausch + Lomb Corporation
―
Ownership Overview
0.68% Insiders
42.65% Mutual Funds
5.17% Other Institutional Investors
29.25% Public Companies and
Individual Investors